Carrella et al., 2016, have attempted to repurpose FDA approved drug to target computational repurposing for oncogenic PI3K/AKT/P70S6K-dependent pathways with the help of network pharmacology and shortlisted niclosamide and pyrvinium pamoate as the potential drugs for for cancer treatment47. This evidence concerns the gene AKT1 and cancer.